-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $445

Benzinga·10/01/2026 18:42:03
Listen to the news
JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $425 to $445.